
The Wolf of Value Valley
312 posts

The Wolf of Value Valley
@Elfieeen
Forensic auditor.Not financial advice. Hunting balance sheet lies and ticking time bombs the crowd ignores. | PROTOCOL AEGIS | Exposing what the CEO won’t tell.










The "Paid Discord Deep Dive" illusion ends today. Let's do some real institutional math for FREE. > A FinTwit "guru" just posted a list of 22 tickers ($ASTS, $ZETA, $IREN, etc.) claiming nobody can match the "value" of his paid group's deep dives. Here is the reality: Most paid Discords charge you $50/month to draw Fibonacci lines on overvalued SaaS companies and call it "alpha," while completely ignoring cash flow destruction and massive insider dumping. I am taking his challenge. Pick ANY ticker from his list and drop it in the replies. > The most requested ticker gets a full, unredacted Aegis Forensic Audit completely free. We will tear apart the balance sheet, expose the insider money flow, calculate the true FCF Yield, and find the real Margin of Safety. Institutional corporate finance vs. Discord hopium. You decide. Drop the ticker below. 👇🐺


$DLTR $DG $DELL $FRT $SW $HST $LVS $GL $VICI $CPT These specific names survived the most ruthless forensic threshold in our model. Today, we are releasing the fully unlocked, premium dossier for the #1 Risk-Reward anomaly directly to the public. Starting the sequence with: $DLTR. *** AEGIS PROTOCOL: DLTR Archetype: CONSUMER DEFENSIVE EXECUTIVE SUMMARY RECOMMENDATION: ACCUMULATE / OVERWEIGHT TARGET FAIR VALUE: $165.66 KELLY ALLOCATION: 21% ( HALF KELLY 10% to reduce over exposure ) CORE ASYMMETRY: We are looking at a crystal-clear quantitative anomaly. The spin-off of the massively unprofitable Family Dollar anchor has transformed DLTR into a pure stand-alone business. It now generates an uncompromising $3.0 Billion in real operating cash flow. Crucially, this firm does not bleed capital through toxic executive stock options. While the market panics over retail shrinkage, it completely ignores the pristine F-Score of 8/9 and a textbook Margin of Safety that creates a gigantic EV/Risk-Reward Ratio of 1:20 in favor of safety. Aggressive accumulation is warranted. I. COMPANY OVERVIEW & BUSINESS MOAT Dollar Tree is a giant of defensive consumer retail. After years of painful integration, it finally severed its anchor by spinning off Family Dollar to private equity. The new era is Multi-Price 3.0. Dollar Tree stores are no longer traps for strictly $1.25 items; they are a structured retail environment offering merchandise at $3, $5, and $7. This brutally expands the marginal profit per square-foot, all while capturing middle-class consumers fleeing from overpriced hubs like Target. II. THE INTRINSIC MISPRICING The market heavily punishes physical retail and inherently distrusts it after the pandemic rollercoaster. Furthermore, Wall Street is chronically efficient at pricing narratives, but heavily lags in pricing immediate, hard cash when it doesn't wear an AI mask. - Chuck Akre Return on Incremental Invested Capital registers an absolutely elite 31.9%. - At the current price of ~$101.33, the Discounted Cash Flow model anchors the absolute fair value at $165.66. As a result, the firm carries an immense Margin of Safety. You are paying roughly sixty cents on the dollar for corporate earnings and free cash. There is no revenue breakdown, no accounting fraud. There is only a total lack of interest from Wall Street, currently oscillating somewhere between Nvidia and bond bailouts. This is the origin of the mammoth 21.0% Kelly Fraction allocation. III. MACRO BACKDROP & CATALYST HORIZON - MACROECONOMIC LIQUIDITY: Any slight economic downturn or continued M2 stagnation plays directly into the company's hands. The chain profits immensely from trade-down consumer behavior. - CATALYST 1: Supply Chain savings realization. An influx of capital injection from March 2026 will improve transport sourcing and Asian margins. When these results hit the Q3/Q4 earnings calls, the market will experience a re-rating of the stock back into the $130+ range. - CATALYST 2: Complete removal of the spin-off noise from the books, resulting in exquisitely clean GAAP YoY earnings comparisons. IV. FORENSIC ACCOUNTING TEAR-DOWN A masterpiece for a fundamental value investor. No manipulation found. The Beneish M-Score of -3.41 sits deeply inside the safe zone. A Piotroski F-Score of 8/9 signals a textbook-clean, flourishing balance sheet. But the ultimate weapon is the lack of Stock-Based Compensation. The executive board takes roughly $60M a year in stock, relentlessly funneling the real cash into the underlying business and preparing massive potential buybacks. Zero vampire bleeding. V. TACTICAL BEAR THESIS DEFEAT Anyone claiming DLTR is a value trap fails to understand the recent entity separation. The risks here lie directly in geopolitics rather than corporate incompetence. Probability Weighted Scenario Analysis: - 80% Probability: As the $7 item limit takes root, margins will steadily expand. Over the next 18 months, the market will re-price the firm toward its true DCF boundary of $140 - $160 per share. - 20% Probability: America introduces brutal import tariffs on cheap plastics and Asian goods. Logistics grind to a halt, shrinkage becomes uncontrollable via weak prosecution, and DLTR trims 1,000 stores from its footprint. Price drops to $70. EXISTENTIAL RISK FACTOR: A macroeconomic US-China tariff war acting as a lethal tax on the low-margin business models. VI. EXECUTION ARCHITECTURE Tranche-based accumulation via Quant engine: - ENTRY 1: $101.33 (Allocation: 2.5% of Portfolio NAV) - ENTRY 2: $99.30 (Allocation: 5% of Portfolio NAV) -> Primary Accumulation Wall - ENTRY 3: $93.90 (Allocation: 2.5% of Portfolio NAV) -> Maximum Buy Limit. Any price action falling below the $93.90 threshold would necessitate an immediate halt on accumulation to verify if any new, unpriced negative catalysts are developing around the asset. Not financial advice, manage your own risk.





@himshouse Retail is treating HIMS like a guaranteed winner. My forensic protocol, AEGIS, just hit it with a Fatal Red Flag for unsustainable dilution and a 207 Debt/Equity ratio. Do not be exit liquidity. Read the autopsy on my page before buying the dip.

E208: Un negocio más grande que la IA. Antonio Linares @alc2022 @holdmybirra @dariopalacio @Gordoneaprod


$HIMS 4-5 YEAR PROJECTION Wave 5 PT = $200, +690% gain by 2030 In spite of what many felt was a strong pull back for Wave 2, it was fairly standard, with a retest of the 200 WMA and the 0.78 Fib Now we are in Wave 3 Wave 3 arriving on time as a number of tailwinds are behind us. $HIMS will be our next +1000% gainer in this cycle. Share.



🚨 $HIMS ANALYST UPDATES Needham raises PT to $35 (Buy rating) Canaccord raises PT to $32 (Buy rating) Citi raises PT to $28 (Hold rating)







Další pandemie dřív nebo později přijde🦠 Historicky se to opakuje řekněme jednou za 50-100 let. Teď je situace horší hlavně kvůli rozvoji cestování, návštěv exotických oblastí, kácení pralesů a kontaktu s divokými zvířaty. Ve většině případů vznikne mutací zvířecího viru, který se začne přenášet mezi lidmi. Je to loterie, viry neustále náhodně mutují. V posledních letech za největší riziko považujeme mutaci H5N1 ptačí chřipky. Ta se občas ze zvířat dostane na člověka a zhruba v polovině případů to skončilo smrtí. Zatím nezmutovala tak, aby se efektivně šířila z člověka na člověka, ale pokud se to stane, potenciál na pandemii je obrovský. Teď se v médiích skloňuje hantavirus, konkrétně v jihoamerické variantě, která již umí přenos z člověka na člověka a aktuálně zabila několik lidí na výletní lodi. Smrtnost kolem 35%, neexistuje vakcína. Podle WHO je šance na pandemii v tomto případě velmi nízká. Podle Polymarketu 9%. Poslední měsíce více pronikám do biotech sektoru a zabýváme se touto problematikou. Ukazuje se, že AI hodně pomáhá ve vývoji nových molekul. V rukou určitých skupin roste riziko rozvoje biologických zbraní a případně umělé modifikaci zvířecích virů k přenosu z člověka na člověka. S viry se v laboratořích běžně experimentuje. Podle Interpolu existují skupiny, které se tímto aktivně zabývají. Odborné zdroje uvádí každý rok šanci na pandemii zhruba 2-5%. Podle Polymarketu 10-20%. Predikční server Metaculos uvádí pravděpodobnost přes 50% na pandemii před rokem 2030. Tomu se ani nedá říkat černá labuť. Doufat že se to nestane je naivní. Statisticky se to dřív nebo později stane. Přijde mi rozumné se na to připravovat i jako portfolio manažer. Rozhodně je výhoda mít vše zanalyzované předem. Je to jeden z důvodů, proč teď s týmem hledáme oportunity zejména v sektoru zdravotnictví a biotech.





